An observational study in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Observational
This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 19,870 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients of general practioners, cardiologists and specialist in internal medicine in non-hospital practice
Inclusion Criteria:
Exclusion Criteria: (Not applicable)
Drug: Micardis®
Indicence of ulcera
Time frame: Up to 6 months after start of study
Incidence of gastrointestinal (GI) bleedings
Time frame: Up to 6 months after start of study
Incidence of adverse events (GI-complaints inclusive)
Time frame: Up to 6 months after start of study
Change from baseline in office blood pressure
Time frame: Up to 6 months after start of study
Response rate
full response: reduction of diastolic blood pressure (DBP) by \>= 10 mmHg or final DBP \<= 90 mmHg overall response: reduction of DBP by \>= 7mmHg or final DBP \<= 90 mmHg
Time frame: Up to 6 months after start of study
No study locations are listed for this record.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim